Response Genetics (RGDXQ) Stock Price

Response Genetics Price

OTC·CLOSED
0.00
​
Market closed

Over the last 11 years Response Genetics grew revenue by 16.2% annually, reaching 18.04 M USD. For Response Genetics, the net margin of -111.9% is down versus -25.3% a few years ago.

Response Genetics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Response Genetics business model & stock analysis

Response Genetics, Inc. generates revenue through the research, development, and sale of pharmacogenomic diagnostic tests for cancer treatment. The company offers ResponseDX diagnostic testing products, which utilize polymerase chain reaction, microarray methods, and fluorescence in situ hybridization (FISH) to analyze single biomarkers or gene profiles from patient tissue samples. Pharmaceutical companies in the United States, Asia, and Europe purchase the firm's pharmacogenomic clinical trial testing services, which provide genetic information from patient specimens to support drug development. The company's primary market segments include oncology-focused healthcare providers and pharmaceutical firms seeking to integrate genetic data into cancer therapy protocols. Response Genetics' revenue streams are derived from both direct sales of diagnostic products and contract-based clinical trial services. The firm's pharmacogenomic tests are designed to guide cancer treatment decisions by analyzing genetic markers, while its clinical trial services cater to pharmaceutical companies developing new oncology drugs. The company's product portfolio centers on ResponseDX, which is marketed to healthcare institutions and integrated into clinical workflows for personalized cancer care. The business model relies on the sale of diagnostic testing services and clinical trial support to pharmaceutical clients across multiple regions. Response Genetics' testing platforms enable the extraction and analysis of nucleic acids from patient samples, delivering actionable pharmacogenomic data. This data is used by pharmaceutical companies to tailor drug development and by healthcare providers to personalize treatment plans for cancer patients.

Frequently asked questions about Response Genetics

Converted at the current exchange rate, the Response Genetics share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Response Genetics.

The profit cannot currently be calculated for Response Genetics.

The P/E ratio cannot be calculated for Response Genetics at the moment.

The P/S cannot be calculated for Response Genetics currently.

The Eulerpool Quality Score for Response Genetics is 3/10.

The ISIN of Response Genetics is US76123U1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Response Genetics is RGDXQ. The ticker symbol is used to trade Response Genetics shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
187,916.67 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Jun 5, 2007
ISIN
US76123U1051
Cusip
76123U105
Market capitalization
3,875.56 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2016
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-51.24 %
Last updated Oct 24, 2026, 7:15 AM

Response Genetics Peer Group

Response Genetics Ticker

OTC · RGDXQOTC · RGDXQ

Response Genetics FIGI

RGDXQ:US · BBG000QLZCD5RGDXQ:PQ · BBG000QLZLS9RGDXQ:UV · BBG000QLZMD3